Intervention Review

Creatine for amyotrophic lateral sclerosis/motor neuron disease

  1. Daniel M. Pastula1,*,
  2. Dan H Moore2,
  3. Richard S Bedlack3

Editorial Group: Cochrane Neuromuscular Disease Group

Published Online: 16 JUN 2010

Assessed as up-to-date: 14 OCT 2009

DOI: 10.1002/14651858.CD005225.pub2

Database Title

Additional Information

How to Cite

Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No.: CD005225. DOI: 10.1002/14651858.CD005225.pub2.

Author Information

  1. 1

    UCSF Medical Center, Neurology, San Francisco, California, USA

  2. 2

    California Pacific Medical Center, Research Institute, San Francisco, CA, USA

  3. 3

    Duke Medical Center, Division of Neurology, Durham, USA

*Daniel M. Pastula, Neurology, UCSF Medical Center, UCSF Neurology, Box 0114, 505 Parnassus Ave, San Francisco, California, 94143-0114, USA. Daniel.Pastula@ucsfmedctr.org.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 16 JUN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (57K)Standard (352K)Full (358K)

  1. Current Version

    Creatine for amyotrophic lateral sclerosis/motor neuron disease

    Daniel M. Pastula, Dan H Moore and Richard S Bedlack

    Article first published online: 16 JUN 2010 | DOI: 10.1002/14651858.CD005225.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Creatine for amyotrophic lateral sclerosis/motor neuron disease

    Richard S Bedlack and Milan C Mathew

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD005225

View Full Article (HTML) Summary (57K)Standard (352K)Full (358K)